Danaher said net earnings for Q2 2025 ended June 27, 2025 were $555 million, or $0.77 per diluted common share, and revenues increased 3.5% to $5.9 billion. Non-GAAP core revenue increased 1.5%.

1. 01

   Danaher said net earnings for Q2 2025 ended June 27, 2025 were $555 million, or $0.77 per diluted common share, and revenues increased 3.5% to $5.9 billion. Non-GAAP core revenue increased 1.5%.

2. 02

   The company said operating profit for Q2 was $760 million, below $1,168 million in the comparable prior-year period (in millions), and reflected a trade name impairment charge of $432 million (pretax) in the Life Sciences segment in the quarter. Adjusted diluted net earnings per common share were $1.80.

3. 03

   Danaher disclosed that operating cash flow for Q2 (3 months) was $1,338 million and non-GAAP free cash flow was $1,094 million. Free cash flow equals operating cash flow less capital expenditures of $248 million plus proceeds from capital disposals of $4 million.

4. 04

   The company raised its full-year 2025 adjusted diluted net earnings per common share guidance to $7.70 to $7.80 from prior guidance of $7.60 to $7.75, and said there is no change to its expectation that non-GAAP core revenue will grow approximately 3% for the full year.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.